-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Soft tissue sarcoma (STS) is a rare and heterogeneous stromal tumor
We conducted an open-label, multi-institution, single-arm, phase II clinical trial of single cabozantinib in patients with aggressive advanced STS who had received at least one standard systemic therapy
The primary endpoints were overall response rate and 6-month progression-free survival (PFS)
Assess the patient's best response
Assess the patient's best responseThe median treatment course was 4 (range 1-99)
Objective responses (all partial responses) were achieved in 6 (11.
progression-free survival
progression-free survivalThe most common grade 3-4 adverse reactions were hypertension (7.
side effects
side effectsIn conclusion, cabozantinib alone has demonstrated modest resistance in STS patients with specific histologic subtypes (alveolar soft sarcoma, undifferentiated pleomorphic sarcoma, extraskeletal myxoid chondrosarcoma, and leiomyosarcoma).
Cabozantinib showed certain antitumor activity as a single drug Cabozantinib showed certain antitumor activity
Original source:
Original source:Geraldine O'Sullivan Coyne, et al.
leave a message here